SAINT-PREX, Switzerland-Tuesday, October
(BUSINESS WIRE) -- Ferring Pharmaceuticals announced today that Professor Klaus Dugi has been appointed Executive Vice President and Chief Medical Officer, effective immediately.
He will be responsible for Global Medical Affairs, Quality Assurance and Pharmacovigilance. In addition, he will also be a member of the Ferring Executive Board.
Prior to this role, Prof. Dugi held various leadership roles at Boehringer Ingelheim, including Vice President Global Medical Affairs, Chief Medical Officer, and, most recently, Managing Director UK & Ireland.
“Making the industry more patient-centric has always been a top priority for Professor Dugi, and this is perfectly aligned with our company philosophy and commitment to solving unmet patient needs, particularly in the area of reproductive and maternal health,” said Michel Pettigrew, President of the Executive Board and Chief Operating Officer, Ferring Pharmaceuticals.
A Professor of Medicine, with a
About Ferring Pharmaceuticals:
Headquartered in Saint-Prex, Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. A leader in reproductive and maternal health, Ferring has been developing treatments for mothers and babies for over 50 years. Today, over
Ferring is on Twitter. Follow us @FerringNews at http://twitter.com/FerringNews
Contacts
Ferring Corporate Communications Team:
Lindsey Rodger
Senior Manager, Corporate Communications
+41 58 451 4023 (direct)
+41 79 191 0486 (mobile)
lindsey.rodger@ferring.com
or
Bhavin Vaid
Head of Corporate Communications
+41 58 301 0952 (direct)
+41 79 191 0632 (mobile)
bhavin.vaid@ferring.com
Permalink : http://aetoswire.com/news/4707/en
No comments:
Post a Comment